Energenesis Biomedical Co., Ltd. (6657) AI Stock Analysis

Energenesis Biomedical Co., Ltd.

(TWSE:6657)

Select Model

Rating:38Underperform

Price Target:TWD 28.00▼(-6.67% Downside)

Action:initiatedcoverage

Date:11/10/26

The score is primarily constrained by persistent losses and severe cash burn. Very low leverage provides some financial flexibility, but weak profitability, negative cash flow, bearish technical positioning, and a negative P/E result in a near-floor overall score.

Positive Factors

Low Leverage and Equity CushionVery low leverage reduces mandatory financing pressure and gives the company greater flexibility to fund operations or absorb volatility. The substantial equity base provides a balance-sheet cushion, which is particularly valuable while the business works to improve profitability and cash generation.

Negative Factors

Persistent Deep LossesPersistent losses show that the company has not yet established a viable earnings model despite its strong gross margins. Continued negative profitability can erode equity over time and limits internally funded investment, making a durable improvement in operating leverage essential.

Energenesis Biomedical Co., Ltd. (6657) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 2.64B
Dividend Yield: ―
Average Volume (3M): 162.70K
Price to Earnings (P/E): -8.8
Beta (1Y): 0.55
Revenue Growth: -4.36%
EPS Growth: 1.97%
Country: TW
Employees: 35
Sector: General
Sector Strength: 55
Industry: Biotechnology

Energenesis Biomedical Co., Ltd. Business Overview & Revenue Model

Company Description

Energenesis Biomedical CO.,LTD., a firm established in 2012 and headquartered in Taipei, Taiwan, is an active participant in the biomedicine sector. The company specializes in the development of a diverse range of medical solutions and research mater...

Energenesis Biomedical Co., Ltd. Financial Statement Overview

Summary

Persistent substantial losses and deeply negative operating and free cash flow outweigh the very low debt-to-equity ratio and improving assets and equity.

Income Statement

12Very Negative

Balance Sheet

82Very Positive

Cash Flow

10Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	7.64M	7.67M	7.75M	7.16M	7.35M	7.49M
Gross Profit	-470.00K	5.83M	5.69M	5.23M	5.17M	5.36M
EBITDA	-298.41M	-252.70M	-208.06M	-238.02M	-241.04M	-97.05M
Net Income	-298.61M	-258.40M	-231.08M	-260.38M	-265.66M	-120.24M
Balance Sheet
Total Assets	784.06M	948.98M	780.64M	828.57M	630.86M	885.81M
Cash, Cash Equivalents and Short-Term Investments	677.38M	838.10M	664.98M	699.20M	484.67M	725.84M
Total Debt	11.74M	14.84M	10.03M	8.28M	9.54M	11.94M
Total Liabilities	71.14M	52.71M	41.30M	24.59M	28.31M	33.44M
Stockholders Equity	712.93M	896.27M	739.33M	803.98M	602.56M	852.38M
Cash Flow
Free Cash Flow	-233.64M	-224.72M	-181.47M	-225.89M	-239.43M	-106.18M
Operating Cash Flow	-230.55M	-222.41M	-180.71M	-225.05M	-232.84M	-97.29M
Investing Cash Flow	376.68M	91.83M	193.23M	-58.96M	175.42M	-115.76M
Financing Cash Flow	-43.79M	399.34M	145.28M	440.42M	-1.75M	287.98M

Energenesis Biomedical Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:6657 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:6733	46Neutral	TWD 2.80B	-38.91	―	―	10.74%	21.61%
TW:6461	42Neutral	TWD 2.94B	-5.89	―	―	-57.87%	-21.67%
TW:6657	38Underperform	TWD 2.69B	-8.85	―	―	-4.36%	1.97%

* General Sector Average

Performance Comparison

TW:6657 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:6657	Energenesis Biomedical Co., Ltd.	30.00	-11.10	-27.01%
TW:6461	Intech Biopharm Ltd	26.55	1.66	6.65%
TW:6733	BioGend Therapeutics Co., Ltd.	20.85	-18.33	-46.78%
TW:6918	A Plus Biotechnology Co Ltd	74.70	-7.94	-9.60%
TW:6926	Shine-On Biomedical Co., Ltd.	60.00	-11.30	-15.85%
TW:6955	Bonraybio Co. Ltd.	86.00	-47.88	-35.76%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026

Energenesis Biomedical Co., Ltd. AI Stock Analysis